UK markets close in 3 hours 53 minutes

Inventiva S.A. (0RNK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
9.00+0.18 (+1.98%)
As of 04:59PM BST. Market open.
Full screen
Previous close8.82
Bid0.00 x N/A
Ask0.00 x N/A
Day's range9.00 - 9.00
52-week range9.00 - 9.00
Avg. volumeN/A
Market cap171.079M
Beta (5Y monthly)1.00
PE ratio (TTM)N/A
EPS (TTM)-1.27
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022

    Daix, May 19, 2022 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. (the “Company”) as approved by the Ordinary General Meeting of May 19, 2022. Securities concerned: shares issued by Inventiva S.A. Maximum proportion of capital that may be purchased by the Company: 10% of the total number of shares comprising t

  • Globe Newswire

    Inventiva reports 2022 First Quarter Financial Information and provides clinical development update

    Cash position2 at €80.5m as of March 31, 2022The Group did not generate any revenue in Q1 2022Signature of a €50 million bullet credit facility agreement with the European Investment BankUpdate on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as for the two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Na

  • Globe Newswire

    Inventiva secures a €50 million credit facility from the European Investment Bank

    This credit facility is intended to support the progress and expansion of Inventiva’s pipelineThe credit facility consists of two tranches of €25 million eachCredit agreement is part of the European Investment Bank’s strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinic